ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO086

Contrast-Related Risk of Progressing to ESRD in Patients Undergoing Percutaneous Coronary Intervention: Iohexol vs. Iodixanol

Session Information

Category: Acute Kidney Injury

  • 101 AKI: Epidemiology, Risk Factors, and Prevention


  • Chang, David R., China Medical University Hospital, Taichung, Taiwan
  • Lu, Sz Ying, China Medical University Hospital, Taichung, Taiwan
  • Lin, Zi-Han, China Medical University Hospital, Taichung, Taiwan
  • Kuo, Chin-Chi, China Medical University Hospital, Taichung, Taiwan
  • Chiang, Hsiu-Yin, China Medical University Hospital, Taichung, Taiwan

Our study aims to determine the differential risk of accelerated progression to end-stage renal disease (ESRD) associated with the contrast agents Iohexol and Iodixanol in patients undergoing percutaneous coronary intervention (PCI). This research is particularly important for addressing concerns about the use of PCI in individuals with chronic kidney disease (CKD).


This matched cohort study identified patients undergoing PCI of China Medical University Hospital between 2003 and 2017. For each patient administered with Iohexol, we identified a corresponding patient who was administered Iodixanol, ensuring that they were matched in terms of age, sex, baseline serum creatinine, and the year of the procedure. We employed multivariable Cox proportional hazard models to evaluate the risk of ESRD in the Iohexol group in comparison to the Iodixanol group. Subgroup analyses were further conducted specifically for patients with and without CKD.


Among a total of 5,335 patients who used Iohexol and an equal number of control patients who used Iodixanol, we noted ESRD incidence rates of 3.47% and 3.26%, respectively. In the subcategory of patients with CKD, the incidence rates were 17.4% and 17.3% respectively for the Iohexol and Iodixanol groups. After adjusting for factors such as hypertension, diabetes, heart failure, medication use, electrolyte levels, and hemoglobin, we found that Iodixanol significantly associated with lower risk of ESRD with an adjusted hazard ratio (aHR) of 0.65 (95% CI, 0.47–0.90; p-value: 0.01), compared with the Iohexol group. In the subgroup analysis, the protective effect was only observed among patients with CKD with an adjusted hazard ratio (aHR) of 0.70 (95% CI, 0.49–0.99; p-value: 0.04).


Our study suggests that Iodixanol is significantly associated with a reduced risk of progression to ESRD following PCI compared to Iohexol in real-world practice. Therefore, when considering contrast agents for these procedures, particularly in CKD patients, Iodixanol emerges as a preferable choice to mitigate the risk of ESRD.

Table 2. Hazard ratios for risk of progression to ESRD


  • Government Support – Non-U.S.